Abstract Alteration of the p53 gene product is a frequent event in the progression of lung cancer. However, its importance to proliferation and response to chemoradiotherapy remains unclear. Thus, to assess its in¯uence directly in vivo, we implanted into nude mice two kinds of human non-small-cell lung cancer (NSCLC) cells: H226br having a homozygous gene mutation in p53 (mtp53) and H226b with intact p53 (wt-p53). We found that mt-p53 tumors grew substantially faster than wt-p53 tumors. Furthermore, treatment with cisplatin and radiation did not reduce the size of mt-p53 tumors, while wt-p53 tumors regressed by approximately 60%. Terminal-deoxytransferase-mediated dUTP-biotin nick-end labeling assay revealed apoptosis to be the mechanism responsible for the regression. Interestingly, apoptosis occurred in mt-p53 tumors although only at high doses of cisplatin and not at the magnitude detected in wt-p53 tumors. Cell labeling by staining with bromodeoxiuridine indicated that p53 is an important factor in modulating growth in NSCLC tumors. Our results are consistent with the notion that correction of a single genetic lesion enhances the therapeutic eect of chemotherapy.
Introduction
The tumor suppressor p53 is a widely studied transcription factor and its inactivation by sense mutation or deletion, the commonest genetic alterations in human cancer (Levine et al. 1991; Hollstein et al. 1991) , occurring in as many as 80% of cases in some cancers (Greenblat et al. 1994) , plays an important role in the pathogenesis of neoplasia.
An altered p53 gene abolishes the tumor-suppressor activity of the p53 protein, facilitating tumor development and increase of metastatic potential and tissue invasiveness (Hsiao et al. 1994) , as has been observed in many types of human cancers, including brain (Sidransky et al. 1992) , breast (Peyrat et al. 1995) and colon cancer (Kastrinakis et al. 1995) . p53 protein has also been shown to play an important role in the response to DNA damage induced by chemotherapeutic drugs and/or ionizing radiation (Tishler et al. 1993) . The mechanism involved entails a rapid increase in p53 protein levels and the mediation of several cellular responses, including (1) G1 arrest via transcriptional induction of p21/WAF21 Chen et al. 1995) , (2) DNA damage repair via transcriptional induction of GADD45 (Kastan et al. 1992) , which interacts with PCNA to carry out this function (Smith et al. 1994) , and (3) induction of apoptosis (Lowe et al. 1993a, b) .
It has been shown that the arrest of the cell cycle at G1 allows cells to repair DNA before S-phase. If optimal repair is impossible, p53 then triggers programmed cell death (Smith et al. 1994; Fritsche et al. 1993) . In tumoral cells with mutant-type p53 (mt-p53), the loss of p53 function, and subsequently the above cellular events, is thought to result in resistance to chemotherapeutic agents (Lowe et al. 1993b; O'Connor et al. 1993 ; Lee and Bernstein 1992; Fan et al. 1994) . However, in some cells, the loss of the G1 checkpoint does not inuence chemoradiosensitivity, since the G2 checkpoint may be a more important determinant of sensitivity (Slichnmyer et al. 1993) . The dierences described probably indicate that the kind of response is a cell-typespeci®c phenomenon.
Recently, studies performed in vitro have provided new insights into the cellular mechanism involved in the induction of apoptosis by chemotherapeutic agents. However, relatively little is known about the relationship between p53 status, apoptosis and DNA damage in vivo. Cisplatin, a DNA-cross-linking chemotherapeutic drug, and radiation, a treatment that produces single-strand breaks in DNA, are widely used to treat locally advanced non-small-cell lung cancer (NSCLC). Unfortunately, few patients develop a complete pathological response. The factors responsible for this lack of response are multiple and not well understood (Reeve et al. 1996; Tsai et al. 1996) . Thus, to elucidate the relation of p53 status to proliferation and response of NSCLC tumors to these agents in vivo, we selected and implanted into nude mice two human non-small-cell lung cancer lines diering only in p53 status.
Materials and methods

Cell lines
The human squamous NSCLC cell line H226br, with a homozygous mutation in p53 (mt-p53) at codon 254, and H226b, having an intact p53 gene [wild type (wt-p53)], were used. H226br is a variant of the H226b cell line derived from a brain metastasis in a nu/nu mouse (gift of I.J. Fidler, the University of Texas M.D. Anderson Cancer, Houston) (Cai et al. 1995) . The H226b cell line was a gift from A. Gazdar and J. Minna (Simmons Cancer Center, Dallas, Texas) and have been previously described (Mitsudomi et al. 1992; Fujiwara et al. 1994) . These tumor cells were maintained in RPMI-1640 medium (Sanko Junyaku Co. Ltd., Tokyo) containing 10% fetal bovine serum.
Animals
Male athymic speci®c-pathogen-free nude mice of a CD-1 genetic background and weighing 20±25 g were obtained from Charles River Japan and used at 4 weeks of age. The mice were kept in sterilized cages equipped with an air ®lter and sterile bedding material, and fed with sterilized water and food ad libitum.
Tumoral cell transplantation and evaluation of antitumor eects H226b and H226br cells (4´10 6 cells /0.2 ml cell suspension) were subcutaneously injected into the back of each mouse. The tumors were measured by length and width, using calipers, three or four times weekly by the same observer. Tumor weight was calculated from linear measurements according to the Battelle Columbus protocol: tumor weight (mg) 1/2´a´b 2 , where a is the length (mm) and b the width (mm).
At around 4 weeks after the inoculation of tumoral cells, when the tumors had reached a weight of around 90±120 mg, tumorbearing mice were randomly allocated to groups with at least ®ve mice in each group and irradiated or intraperitoneally treated with cisplatin. The antitumor response was evaluated using one dosi®-cation and expressed as relative weight, using the following formula: relative tumor weight mean tumor weight at a given time/ initial mean tumor weight.
Apoptotic response to chemo-and radiotherapy
The tumors were allowed to grow for 4 weeks until they weighed about 90±120 mg. Cisplatin (Briplatin; Bristol-Myers Squibb K.K., Tokyo, Japan) was used. The drug at 3 mg/kg and 15 mg/kg was administered i.p. using a 26-gauge tuberculin needle. Mice were sacri®ced 24 h, 48 h and 72 h after treatment and the tumors were resected, ®xed in formalin and embedded in paran to be processed for histological examination by nick-end labeling.
Dierent sets of ®ve tumor-bearing mice were irradiated once with 4 Gy and 12 Gy from a Hitachi Medico (MBR 1520) X-ray generator delivering a dose rate of 1.5 Gy/min. After 24 h, 48 h and 72 h, mice were sacri®ced and tumors were resected for histological evaluation.
Detection of apoptotic cells by in situ DNA nick-end labeling As the reliability has been con®rmed (Veis et al. 1993) , we employed the method described by Gavrieli et al. (1992) for the identi®cation of apoptotic nuclei. In brief, paran sections of formalin-®xed tissues were dewaxed, rinsed in alcohol and allowed to dry. Sections were then digested with proteinase K (20 lg/ml) for 15 min at 37°C and the slides washed four times in doubledistilled water for 2 min. Endogenous peroxidase was inactivated by covering the sections with 2% H 2 O 2 for 5 min at room temperature. The sections were rinsed with double-distilled water and immersed in TDT buer (30 mM Trizma base, pH 7.2, 140 mM sodium cacodylate, 1 mM cobalt chloride). TDT and biotinylated dUTP in TDT buer were added to cover the sections, which were then incubated in a humid atmosphere at 37°C for 60 min. The reaction was terminated by transferring the slides to buer containing 300 mM sodium chloride/30 mM sodium citrate for 15 min at room temperature. The sections were rinsed with double-distilled water, covered with a 2% aqueous solution of human serum albumin for 10 min at room temperature, rinsed in double-distilled water and immersed in phosphate-buered saline (PBS) for 5 min. The sections were treated with peroxidase-conjugated streptavidin (Vectastain Elite ABC Kit) for 30 min at 37°C, washed in doubledistilled water, immersed for 5 min in PBS, stained with diaminobenzidine/H 2 O 2 solution (DAB substrate kit, Histo®ne, Tokyo, Japan) for about 10 min at room temperature and counter-stained with methyl green overnight.
An apoptotic labeling index was calculated after 5000 nuclei in randomly selected ®elds had been counted for each tumor under a light microscope using´40 objective and´10 ocular lenses.
Apoptotic response to chemo-and radiotherapy in vitro
H226b and H226br cells were seeded in RPMI-1640 medium at 37°C in a 5% CO 2 atmosphere in tissue-culture¯asks at 4´10 5 cells/¯ask. On the second day, the medium was exchanged and cisplatin at dierent concentrations was added. Additional cultures without the drug were used as controls. At dierent times, the cells were collected, washed with PBS and smeared by cytospin (1000 rpm for 5 min) on glass slides pretreated with neoprene/toluene solution. The slides were ®xed in cold acetone for 10 min and then air-dried. Slides were then rinsed with PBS, covered with 0.02% Nonidet P-40 for 4 min and washed in PBS for 1 min, four times. Slides were subsequently treated as for the tissue preparations except that the incubation with proteinase K was omitted (Gavrieli et al. 1992) .
Another set with the same cell concentrations and culture conditions was prepared. On the second day of culture, cells were irradiated using a Hitachi, Medico (MBR 1520R) X-ray generator at a rate of 1.5 Gy/min at various doses. At dierent times, the cells were collected and prepared for nick-end labeling as above.
Identi®cation of bromodeoxyuridine(BrdU)-labeled cells
Mice were sacri®ce 90 min after intraperitoneal (i.p.) injection of 10 mg/kg BrdU. Tumors were resected, ®xed in formalin, and embedded in paran. For immunohistochemical staining, the sections were deparanized, washed with distilled water for 5 min, and incubated with 0.3% H 2 O 2 in methanol for 30 min to inactivate endogenous peroxidase. Washed with PBS, these sections were boiled in citrate buer solution (pH 6.0) in an autoclave at 120°C for 15 min. After washing in PBS for 20 min, the sections were incubated in normal horse serum for 20 min at room temperature. They were then incubated with primary antibody for 12 h at 4°C in a moisture chamber. A Vectastain Elite kit (Vector Laboratories, Burlingame, Calif., USA) was used to apply the biotinylated secondary antibody (incubated for 30 min at room temperature), then avidin-biotin complex conjugated to horseradish peroxidase was applied (incubation for 30 min at room temperature). After washing in PBS for 10 min, these sections were incubated in diaminobenzidine/H 2 O 2 solution (DAB substrate Kit, Histo®ne, Tokyo, Japan) for 10±15 min at room temperature. As a negative control, a primary antibody was used for mouse IgG. For counterstaning, sections were incubated in methyl green solution. As a primary antibody, mouse monoclonal antibody Bu20a (Magaud et al. 1989 ) (diluted 1:20) was used.
Flow cytometry
H226b and H226br cells (1´10 6 ) were treated with cisplatin and radiation. After being suspended in trypsin, cells were washed in PBS, ®xed in 70% ethanol and stored at 4 o C. Cells were then washed with PBS, treated with RNase (500 units/ml) and Triton X-100 and ®nally stained with propidium iodide at 100 lg/ml in PBS. Cell-cycle analysis was performed on a¯ow cytometer FACS Calibur (Becton Dickinson) and Cell Quest software provided by the manufacturer. A sample of 20000 cells was counted for each determination.
Determination of p53 status
Western blot analysis
After trypsinization, cells were washed once with ice-cold PBS, then solubilized in sodium dodecyl sulfate (SDS) sample buer (125 mM TRIS pH 6.8, 4% SDS, 20% glycerol). Lysates were sonicated on ice and centrifuged at 15 800´g for 15 min. The supernatant was stored at A70°C. Protein concentrations were determined by DC protein assay (Bio-Rad). Total cell lysates were run on SDS/polyacrylamide gels and transferred to nitrocellulose membranes. Western blots were done using a 1:1000 dilution of anti-p53, followed by a 1:10 000 dilution of secondary anti-mouse IgG conjugated to horseradish peroxidase. Bands were visualized on autoradiography ®lm with enhanced chemoluminescence detection reagents (Amersham Life Science). For a primary antibody, we used mouse monoclonal antibody Pab 1801.
Immunocytochemical staining for identifying p53 protein accumulation
Cytospin preparations were ®xed in ethanol for 10 min. Subsequent steps were done as described in BrdU labeling. Primary antibody Pab 1801 (diluted 1:500) was used.
Statistical analysis
Data were analyzed by the Mann-Whitney test.
Results
The p53 status of the cell lines used was unchanged, as con®rmed by Western blotting and immunocytochemical methods (Figs. 1, 2) .
Tumor growth
Growth rates of tumors derived from H226b and H226br cells were strongly in¯uenced by the presence or absence of activity of the p53 gene product (Fig. 3) . Until around day 40, the growth rate of both types of tumors was similar, with the mt-p53 tumors somewhat predominating. Thereafter, however, the growth of tumors with mutant p53 accelerated signi®cantly. Inhibition of tumor growth by cisplatin and radiation
The eect of cisplatin administration is shown in Fig. 4 . By day 2 after the administration of 3 mg/kg and 15 mg/ kg cisplatin, the wt-p53 tumors (Fig. 4A ) had already shown a regression of about 14% and 29% respectively. This response continued until day 7, when the regression was maximum (60%) and then growth slowly re-started. At all assay times, the regression was accentuated in the tumors treated with high doses.
In tumors of mt-type p53 (Fig. 4B) , the main eect was a delay in growth, which lasted for around 1 week and, again, the more marked response was observed in tumors treated with high doses. No regression was observed.
Radiation of wt-p53 tumors at 4 Gy and 12 Gy led to a reduction in tumor size to around 78% and 55% of the pre-treatment size by days 2 and 4 respectively, but this response was of short duration and, around day 3, growth re-started. mt-p53 tumors showed a similar response although slower (Fig. 5) .
Apoptosis induced by chemoradiation
Cells with features of apoptosis were detected by the terminal-deoxytransferase-mediated deoxyuridine-triphosphate±biotin nick-end labeling method (Fig. 6) . The apoptotic response to cisplatin is shown in Fig. 7 . Apoptosis was induced in both tumor types although to what extent related directly to p53 status. Within 24 h after administration of cisplatin, the percentage of apoptotic cells was higher in wild-type than mutated tumors (P < 0.001). This response persisted for 48 h and 72 h after treatment. In mt-p53 tumors, the highest re- experiments. h Control, n 3 mg, n 15 mg sponse was seen 48 h after treatment, but only after administration of a high dose cisplatin, and it never reached the level observed in wt-p53 tumors. A degree of apoptosis was also observed in untreated tumors.
Neither tumor type showed a sustained increase in the percentage of apoptotic cells after radiation, by nickend labeling. Only 6 h after irradiation did the number of apoptotic cells increase in the wt-p53 tumors to around 2% of the total cells, and this subsequently declined sharply to pretreatment values without further increase (data not shown).
Labeling with BrdU
Marked dierences between the two tumor types were observed after treatment with cisplatin ( Fig. 8) , In the wild-type tumors, a slight decrease in the number of labeled cells was observed (no statistical dierence was found) although this decrease was accentuated in tumors treated at high doses. The opposite eect was induced in tumors of mt-p53. The response was maximized at low dose 72 h after treatment and at high dose 48 h after. Thereafter, the number of labeled cells decreased.
BrdU is a pyrimidine analog incorporated into cells during the DNA synthesis phase (S-phase). Therefore, (Quinn and Wright 1992) .
Thus in the ®rst hours after the administration of cisplatin, the presence of wild-type p53 correlated with a decrease in the number of cells in S-phase. However, when p53 function was lost, tumoral cells in the S-phase accumulated.
In irradiated tumors, the response was similar for both tumor types, though more marked in wt-p53 tumors. The response varied in mt-p53 tumors (data not shown).
Apoptosis induced by chemoradiation in vitro
In vitro, exposure to cisplatin induced apoptosis in both tumor types (Fig. 9) ; however, the grade of response was quite dierent. While, in wt-p53 cells, a concentration of 0.5 lg/ml cisplatin was enough to induce a signi®cant increase in the number of apoptotic cells, 10 lg/ml was needed for mt-p53. The magnitude of response also diered at lower doses of cisplatin.
An apoptotic response occurred in irradiated cells, but it did not correlate with dose and/or p53 status (data not shown).
Cell-cycle analysis using¯ow cytometry Fluorescence-activated cell sorting analysis 24 h after treatment of wt-p53 cells with cisplatin revealed an increase in G0/G1 cells with a simultaneous decrease of cells in S-phase, an eect enhanced at 1.0 lg/ml (Table 1). mt-p53 cells showed no change in relation to G0/ Fig. 7A , B. Apoptosis induced by administration of cisplatin at 3 mg/kg (A) and 15 mg/kg (B) in mice bearing wild-type p53 (black bars) and mutant-p53 (shaded bars) tumors. Data represent the mean SE *P < 0.001 Fig. 8A , B Eect of administration of cisplatin at 3 mg/kg (A) and 15 mg/kg (B) on BrdU-labeled cells (S-phase cells) of tumors with dierent p53 status. Black bars wild type p53 tumors, shaded bars mutant p53 tumors, Data represent the mean SE *P < 0.001 against control G1 cells; however, S-phase cell numbers rose after 24 h. At 10 lg/ml, the number of S-phase cells returned to pretreatment values. No G2M arrest was evident.
When wt-p53 cells were irradiated, the number of G0/ G1 cells had increased at 24 h. However there was no change in S-phase cell numbers at that time. In mt-p53 cells, a decrease in the number of G0/G1 cells accompanied an increase in cells in S-phase (data not shown).
Discussion
In cancer, the p53 gene product, a nuclear phosphoprotein, has been related to proliferation and response to DNA damage by chemotherapeutic agents. In lung cancer, alteration of p53 occurs in around 60% of cases (Chiba et al. 1990 ) and has been proven to be of prognostic signi®cance especially in NSCLC (Fujino et al. 1995) .
In this study, we sought to determine in vivo (1) the importance of this factor in the growth of lung tumors; (2) the relationship between p53 status and the eect of chemoradiotherapy, (3) the importance and eect of p53-dependent and -independent apoptosis in the response to chemoradiation and (4) the in¯uence of p53 status on the response of the cell cycle to DNA-damaging agents.
One of the main functions of p53 is suppression of cell proliferation, although the precise mechanism of this suppression is unknown (Allred et al. 1993) . Both in vitro and in vivo, this function has been re-established after the introduction of a p53 gene with a virus vector (Fujiwara et al. 1994; Liu et al. 1994) . However, loss of function is not the only factor responsible for the increased tumorogenesis seen in tumors without p53. It has been reported that transfection of mt-p53 in human osteosarcoma and T cell acute lymphoblastic leukemia produces a gain of function facilitating tumor development and metastatic potential (Dittmer et al. 1993; Hsiao et al. 1994) .
To test in vivo the importance of this factor in the development of tumors in lung cancer, we selected two human NSCLC lines with similar genetic characteristics, diering only in p53 status. We found that, while the growth of wt-p53 tumors was relatively slow, that of mtp53 tumors was uncontrollable. This would not be surprising considering that the mutation of the cells used in this experiment is located between codons 100 and 295 (speci®cally codon 254), which is considered a critical region essential for growth suppression (Srinivasan et al. 1993) . Therefore, the lost of activity of the p53 gene could be responsible for the accelerated growth observed in the mt-p53 tumors. Considering that around 60% of NSCLC tumors present some kind of mutation in the p53 gene, this fact could explain, at least in part, their poor prognosis, especially in patients in whom the tumor is not surgically resectable because of extensive local invasion.
However, the potential prognostic importance of this factor in NSCLC is not limited. A recent report has linked anomalous p53 expression with resistance to chemotherapy (Rusch et al. 1995) . In fact, the chemotherapeutic regimens are based on cisplatin. It has been described how cisplatin, after platination of the DNA and double-strand breaks, causes a reduction in the rate of DNA synthesis with cell-cycle arrest at G2 phase and cell death (Sorenson and Eastman 1988; Sorenson et al. 1990 ). However, its toxicity has been also linked to the presence of p53, as has been demonstrated by in vitro experiments (Lowe et al. 1993b ).
In our in vivo investigation, the tumors induced showed a variable response: wt-p53 tumors showed a regression in size of around 60% in the ®rst week after treatment. The mt-p53 tumors stopped growing, though no regression was observed. Thus, the response to cisplatin in vivo of tumors derived from dierent NSCLC lines was dependent on p53 status. Similar results have been reported in experiments utilizing oncogenically transformed ®broblasts in vivo after administration of Adriamycin (Lowe et al. 1994) . This is of considerable importance because analysis of p53 status, by immunohistochemical or other methods such as the polymerase chain reaction, could make it possible to predict the response to therapy in certain patients.
We also tested the eects of radiation. The response correlated with p53 status, but its eects in wt-p53 tumors was very short, with rapid regrowth. mt-p53 tumors did not shown any response, in accord with previous reports (McIlwrath et al. 1994; Kuerbitz et al. 1992 ). The results obtained are consistent with the clinical experience in which treatment failure is the usual pattern (Johnson et al. 1990 ). The actual evidence is that the p53 status does not correlate with the response to radiation. Apoptosis, a cellular program which, when triggered, sets o a biochemical and morphologically recognizable cascade resulting in cellular suicide, was found to be responsible for the regression in wt-p53 tumors treated with cisplatin. By TUNEL assay, we detected cells with distinctive marks of apoptosis, like shrinkage, nuclear fragmentation, convulsion of the cell surface, and sequestration of the cellular content into membranebound apoptotic bodies (Kerr et al. 1994) .
Apoptotic cells were seen in both kinds of tumor, although their frequency was directly related to p53 status. An increase of wt-p53 in apoptotic cells was evident by 24 h. Thus, apoptosis was responsible for the regression in these tumors. Interestingly, mt-p53 tumors also displayed apoptotic responses but only at high doses of cisplatin and without the same intensity. This p53-independent apoptosis has been also observed in vitro in p53-de®cient mouse embryonic ®broblasts treated with high doses of chemotherapeutic drugs (Lowe et al. 1993b ) and in human prostate cancer (Borner et al. 1995) . Thus, it is thought cells that sustaining a sucient amount of damage undergo apoptosis regardless of p53 status. However, in the tumors tested, this alternative route to apoptosis was not eective in producing tumoral regression. Intact p53 was necessary to achieve a favorable response.
The apoptotic response was also assessed in irradiated tumors. The increase in apoptotic cell numbers was modest and occurred very early in wt-p53 tumors. Moreover, the response varied; therefore, is doubtful that this process plays an important role in toxicity to radiation, at least in the tested cells.
The cell-cycle analysis in vivo, as in vitro, of the wtp53 tumors and cell line showed a decrease in the percentage of S-phase cells following cisplatin treatment, suggesting arrest of the cells at the G1 check-point and apoptosis. However, in vitro we only observed a modest increase in the number of G1 cells, probably because of apoptosis. This notion is reinforced by the ®nding that, in mt-p53 tumors, the number of G1 cells did not change although S-phase cells accumulated. Recently, p53 has been suggested to facilitate progression through S-phase (Hawkins et al. 1996) ; this indicates delay at this stage and subsequent arrest in G2. Further investigation is necessary to clarify this point.
In conclusion, the results presented here show that loss of function of the p53 gene product is an important determinant of increased tumorigenicity in NSCLC tumors. In addition, the response of these tumors to cisplatin depends on the presence of this phosphoprotein, and the mechanism of the response was shown to be apoptosis. The p53-independent apoptosis, induced at high doses of cisplatin in the present study, did not control the growth of tumors. From the clinical point of view, these ®ndings are important and complement the results of a recent clinical study in patients with NSCLC (Rusch et al. 1995) . This suggested that resistance to cisplatin depends mainly on p53 status. This and previous reports support the suggestion that correction of a single genetic lesion can enhance the eect of chemotherapy.
